Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback